The Board of Directors at their meeting convened today have inter alia considered and approved Unaudited Financial Results of the company for the Quarter ended and Nine Months Ended on ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 12.6 pts more than Nifty Microcap 250 and 12.4 pts more than its Other Financial Services peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The Board approved unaudited results for the quarter and nine months ended December 31, 2025. Revenue from operations for 9M FY26 stood at Rs. 148.92 crore, down about 5% from Rs. 156.81 crore in 9M FY25. Q3 FY26 revenue from operations jumped roughly 44% year-on-year to Rs. 62.72 crore, but the company continued to report a net loss of Rs. 7.71 lakh for the quarter and Rs. 9.37 lakh for 9M FY26 (vs. Rs. 9.58 lakh loss a year ago). An exceptional item of Rs. 9.93 lakh was booked in Q3, and a loan of about Rs. 16.11 lakh given to Oasis Nutraceuticals Ltd was written off. The statutory auditor's limited review report is clean, with no qualifications.
The company remains loss-making with negligible margins, and full-year revenue is trending lower despite a strong Q3 rebound. For retail investors, this is a high-risk micro-cap trading company with weak profitability and no visible turnaround in earnings.